Shares of Vaccinex Inc (NASDAQ:VCNX) were up 7.9% on Thursday . The stock traded as high as $6.90 and last traded at $6.28, approximately 309,364 shares traded hands during mid-day trading. An increase of 24% from the average daily volume of 249,168 shares. The stock had previously closed at $5.82.

Several research analysts have recently weighed in on VCNX shares. Zacks Investment Research downgraded shares of Vaccinex from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Oppenheimer reiterated a “buy” rating and set a $22.00 price objective on shares of Vaccinex in a research note on Monday, May 18th.

The company has a market cap of $105.39 million, a price-to-earnings ratio of -2.93 and a beta of 1.20. The firm has a 50-day moving average price of $4.72 and a 200 day moving average price of $4.68.

Vaccinex (NASDAQ:VCNX) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.75) by $0.30. As a group, sell-side analysts expect that Vaccinex Inc will post -1.77 EPS for the current year.

In other Vaccinex news, Director Albert Friedberg bought 1,126,760 shares of the stock in a transaction on Friday, July 10th. The stock was purchased at an average price of $3.55 per share, for a total transaction of $3,999,998.00. Following the completion of the purchase, the director now directly owns 439,555 shares in the company, valued at $1,560,420.25. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 68.60% of the stock is owned by insiders.

Vaccinex Company Profile (NASDAQ:VCNX)

Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.

Featured Article: Quiet Period

Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.